References for Products 15001 to 15025

1. Di L, Kerns EH, Li SQ, Carter GT. (2006) Comparison of cytochrome P450 inhibition assays for drug discovery using human liver microsomes with LC-MS, rhCYP450 isozymes with fluorescence, and double cocktail with LC-MS. Int J Pharm.
2. Lampe JN, Atkins WM. (2006) Time-resolved fluorescence studies of heterotropic ligand binding to cytochrome P450 3A4. Biochemistry, 45, 12204.
3. Turpeinen M, Korhonen LE, Tolonen A, Uusitalo J, Juvonen R, Raunio H, Pelkonen O. (2006) Cytochrome P450 (CYP) inhibition screening: comparison of three tests. Eur J Pharm Sci, 29, 130.
4. Cali JJ, Ma D, Sobol M, Simpson DJ, Frackman S, Good TD, Daily WJ, Liu D. (2006) Luminogenic cytochrome P450 assays. Expert Opin Drug Metab Toxicol, 2, 629.
5. Fernando H, Halpert JR, Davydov DR. (2006) Resolution of multiple substrate binding sites in cytochrome P450 3A4: the stoichiometry of the enzyme-substrate complexes probed by FRET and Job's titration. Biochemistry, 45, 4199.
6. Huwyler J, Wright MB, Gutmann H, Drewe J. (2006) Induction of cytochrome P450 3A4 and P-glycoprotein by the isoxazolyl-penicillin antibiotic flucloxacillin. Curr Drug Metab, 7, 119.
7. Isin EM, Guengerich FP. (2006) Kinetics and thermodynamics of ligand binding by cytochrome P450 3A4. J Biol Chem, 281, 9127.
8. Greenblatt DJ, von Moltke LL, Luo Y, Perloff ES, Horan KA, Bruce A, Reynolds RC, Harmatz JS, Avula B, Khan IA, Goldman P. (2006) Ginkgo biloba does not alter clearance of flurbiprofen, a cytochrome P450-2C9 substrate. J Clin Pharmacol, 46, 214.
9. Zhao Y, White MA, Muralidhara BK, Sun L, Halpert JR, Stout CD. (2006) Structure of microsomal cytochrome P450 2B4 complexed with the antifungal drug bifonazole: insight into P450 conformational plasticity and membrane interaction. J Biol Chem, 281, 5973.
10. Kim D, Wu ZL, Guengerich FP. (2005) Analysis of coumarin 7-hydroxylation activity of cytochrome P450 2A6 using random mutagenesis. J Biol Chem, 280, 40319.
11. Stortelder A, Keizers PH, Oostenbrink C, De Graaf C, De Kruijf P, Vermeulen NP, Gooijer C, Commandeur JN, Van der Zwan G. (2006) Binding of 7-methoxy-4-(aminomethyl)-coumarin to wild-type and W128F mutant cytochrome P450 2D6 studied by time-resolved fluorescence spectroscopy. Biochem J, 393, 635.
12. Kool J, van Liempd SM, Ramautar R, Schenk T, Meerman JH, Irth H, Commandeur JN, Vermeulen NP. (2005) Development of a novel cytochrome p450 bioaffinity detection system coupled online to gradient reversed-phase high-performance liquid chromatography. J Biomol Screen, 10, 427.
13. Kang KD, Jones PD, Huang H, Zhang R, Mostovich LA, Wheelock CE, Watanabe T, Gulyaeva LF, Hammock BD. (2005) Evaluation of alpha-cyano ethers as fluorescent substrates for assay of cytochrome P450 enzyme activity. Anal Biochem, 344, 183.
14. Zhang J, Ha PT, Lou Y, Hoogmartens J, Van Schepdael A. (2005) Kinetic study of cytochrome P450 3A4 activity on warfarin by capillary electrophoresis with fluorescence detection. J Chromatogr A, 1082, 235.
15. Ozalp C, Szczesna-Skorupa E, Kemper B. (2005) Bimolecular fluorescence complementation analysis of cytochrome p450 2c2, 2e1, and NADPH-cytochrome p450 reductase molecular interactions in living cells. Drug Metab Dispos, 33, 1382.
16. Jenkins AT, Dash HA, Boundy S, Halliwell CM, ffrench-Constant RH. (2006) Methoxy-resorufin ether as an electrochemically active biological probe for cytochrome P450 O-demethylation. Bioelectrochemistry, 68, 67.
17. Lussenburg BM, Babel LC, Vermeulen NP, Commandeur JN. (2005) Evaluation of alkoxyresorufins as fluorescent substrates for cytochrome P450 BM3 and site-directed mutants. Anal Biochem, 341, 148.
18. Grasso E, Longo V, Coceani F, Giovanni Gervasi P. (2005) Cytochrome P450 expression and catalytic activity in coronary arteries and liver of cattle. Biochim Biophys Acta, 1722, 116.

19. Wen B, Doneanu CE, Gartner CA, Roberts AG, Atkins WM, Nelson SD. (2005) Fluorescent photoaffinity labeling of cytochrome P450 3A4 by lapachenole: identification of modification sites by mass spectrometry. Biochemistry, 44, 1833.
20. Trubetskoy OV, Gibson JR, Marks BD. (2005) Highly miniaturized formats for in vitro drug metabolism assays using vivid fluorescent substrates and recombinant human cytochrome P450 enzymes. J Biomol Screen, 10, 56.
21. Ogura H, Nishida CR, Hoch UR, Perera R, Dawson JH, Ortiz de Montellano PR. (2004) EpoK, a cytochrome P450 involved in biosynthesis of the anticancer agents epothilones A and B. Substrate-mediated rescue of a P450 enzyme. Biochemistry, 43, 14712.
22. Naritomi Y, Teramura Y, Terashita S, Kagayama A. (2004) Utility of microtiter plate assays for human cytochrome P450 inhibition studies in drug discovery: application of simple method for detecting quasi-irreversible and irreversible inhibitors. Drug Metab Pharmacokinet, 19, 55.
23. Lawson RJ, Leys D, Sutcliffe MJ, Kemp CA, Cheesman MR, Smith SJ, Clarkson J, Smith WE, Haq I, Perkins JB, Munro AW. (2004) Thermodynamic and biophysical characterization of cytochrome P450 BioI from Bacillus subtilis. Biochemistry, 43, 12410.
24. Lawson RJ, von Wachenfeldt C, Haq I, Perkins J, Munro AW. (2004) Expression and characterization of the two flavodoxin proteins of Bacillus subtilis, YkuN and YkuP: biophysical properties and interactions with cytochrome P450 BioI. Biochemistry, 43, 12390.
25. Yoon MY, Campbell AP, Atkins WM. (2004) "Allosterism" in the elementary steps of the cytochrome P450 reaction cycle. Drug Metab Rev, 36, 219.
26. Donato MT, Jimenez N, Castell JV, Gomez-Lechon MJ. (2004) Fluorescence-based assays for screening nine cytochrome P450 (P450) activities in intact cells expressing individual human P450 enzymes. Drug Metab Dispos, 32, 699.
27. Kullman SW, Kashiwada S, Hinton DE. (2004) Analysis of medaka cytochrome P450 3A homotropic and heterotropic cooperativity. Mar Environ Res, 58, 469.
28. Liu CJ, Huhman D, Sumner LW, Dixon RA. (2003) Regiospecific hydroxylation of isoflavones by cytochrome p450 81E enzymes from Medicago truncatula. Plant J, 36, 471.
29. Weaver R, Graham KS, Beattie IG, Riley RJ. (2003) Cytochrome P450 inhibition using recombinant proteins and mass spectrometry/multiple reaction monitoring technology in a cassette incubation. Drug Metab Dispos, 31, 955.
30. Foster BC, Vandenhoek S, Hana J, Krantis A, Akhtar MH, Bryan M, Budzinski JW, Ramputh A, Arnason JT. (2003) In vitro inhibition of human cytochrome P450-mediated metabolism of marker substrates by natural products. Phytomedicine, 10, 334.
31. Dabrowski MJ, Schrag ML, Wienkers LC, Atkins WM. (2002) Pyrene.pyrene complexes at the active site of cytochrome P450 3A4: evidence for a multiple substrate binding site. J Am Chem Soc, 124, 11866.
32. Stresser DM, Turner SD, Blanchard AP, Miller VP, Crespi CL. (2002) Cytochrome P450 fluorometric substrates: identification of isoform-selective probes for rat CYP2D2 and human CYP3A4. Drug Metab Dispos, 30, 845.
33. Arora V, Cate ML, Ghosh C, Iversen PL. (2002) Phosphorodiamidate morpholino antisense oligomers inhibit expression of human cytochrome P450 3A4 and alter selected drug metabolism. Drug Metab Dispos, 30, 757.
34. Renwick AB, Lavignette G, Worboy PD, Williams B, Surry D, Lewis DF, Price RJ, Lake BG, Evans DC. (2001) Evaluation of 7-benzyloxy-4-trifluoromethylcoumarin, some other 7-hydroxy-4-trifluoromethylcoumarin derivatives and 7-benzyloxyquinoline as fluorescent substrates for rat hepatic cytochrome P450 enzymes. Xenobiotica, 31, 861.
35. Kariv I, Fereshteh MP, Oldenburg KR. (2001) Development of a miniaturized 384-well high throughput screen for the detection of substrates of cytochrome P450 2D6 and 3A4 metabolism. J Biomol Screen, 6, 91.
36. Lu P, Lin Y, Rodrigues AD, Rushmore TH, Baillie TA, Shou M. (2001) Testosterone, 7-benzyloxyquinoline, and 7-benzyloxy-4-trifluoromethyl-coumarin bind to different domains within the active site of cytochrome P450 3A4. Drug Metab Dispos, 29, 1473.

37. Nakamura K, Hanna IH, Cai H, Nishimura Y, Williams KM, Guengerich FP. (2001) Coumarin substrates for cytochrome P450 2D6 fluorescence assays. Anal Biochem, 292, 280.
38. Roser R, Thomas H. (2000) A direct, highly sensitive fluorometric assay for a microsomal cytochrome P450-mediated O-demethylation using a novel coumarin analog as substrate. Z Naturforsch [C], 55, 915.
39. Venhorst J, Onderwater RC, Meerman JH, Vermeulen NP, Commandeur JN. (2000) Evaluation of a novel high-throughput assay for cytochrome P450 2D6 using 7-methoxy-4-(aminomethyl)-coumarin. Eur J Pharm Sci, 12, 151.
40. Venhorst J, Onderwater RC, Meerman JH, Commandeur JN, Vermeulen NP. (2000) Influence of N-substitution of 7-methoxy-4-(aminomethyl)-coumarin on cytochrome P450 metabolism and selectivity. Drug Metab Dispos, 28, 1524.
41. Miller VP, Stresser DM, Blanchard AP, Turner S, Crespi CL. (2000) Fluorometric high-throughput screening for inhibitors of cytochrome P450. Ann N Y Acad Sci, 919, 26.
42. Prasad S, Mazumdar S, Mitra S. (2000) Binding of camphor to Pseudomonas putida cytochrome p450(cam): steady-state and picosecond time-resolved fluorescence studies. FEBS Lett, 477, 157.
43. Beckmann-Knopp S, Rietbrock S, Weyhenmeyer R, Bocker RH, Beckurts KT, Lang W, Fuhr U. (1999) Inhibitory effects of trospium chloride on cytochrome P450 enzymes in human liver microsomes. Pharmacol Toxicol, 85, 299.
44. Khan KK, Halpert JR. (2000) Structure-function analysis of human cytochrome P450 3A4 using 7-alkoxycoumarins as active-site probes. Arch Biochem Biophys, 373, 335.
45. Onderwater RC, Venhorst J, Commandeur JN, Vermeulen NP. (1999) Design, synthesis, and characterization of 7-methoxy-4-(aminomethyl)coumarin as a novel and selective cytochrome P450 2D6 substrate suitable for high-throughput screening. Chem Res Toxicol, 12, 555.
46. Moody GC, Griffin SJ, Mather AN, McGinnity DF, Riley RJ. (1999) Fully automated analysis of activities catalysed by the major human liver cytochrome P450 (CYP) enzymes: assessment of human CYP inhibition potential. Xenobiotica, 29, 53.
47. Yamazaki H, Tanaka M, Shimada T. (1999) Highly sensitive high-performance liquid chromatographic assay for coumarin 7-hydroxylation and 7-ethoxycoumarin O-deethylation by human liver cytochrome P450 enzymes. J Chromatogr B Biomed Sci Appl, 721, 13.
48. Lehnerer M, Schulze J, Pernecky SJ, Lewis DF, Eulitz M, Hlavica P. (1998) Influence of mutation of the amino-terminal signal anchor sequence of cytochrome P450 2B4 on the enzyme structure and electron transfer processes. J Biochem (Tokyo), 124, 396.
49. Morse MA, Lu J. (1998) High-performance liquid chromatographic method for measurement of cytochrome P450-mediated metabolism of 7-ethoxy-4-trifluoromethylcoumarin. J Chromatogr B Biomed Sci Appl, 708, 290.
50. Munns AJ, De Voss JJ, Hooper WD, Dickinson RG, Gillam EM. (1997) Bioactivation of phenytoin by human cytochrome P450: characterization of the mechanism and targets of covalent adduct formation. Chem Res Toxicol, 10, 1049.
51. Hoebel BG, Kostner GM, Graier WF. (1997) Activation of microsomal cytochrome P450 mono-oxygenase by Ca2+ store depletion and its contribution to Ca2+ entry in porcine aortic endothelial cells. Br J Pharmacol, 121, 1579.
52. Buters JT, Schiller CD, Chou RC. (1993) A highly sensitive tool for the assay of cytochrome P450 enzyme activity in rat, dog and man. Direct fluorescence monitoring of the deethylation of 7-ethoxy-4-trifluoromethylcoumarin. Biochem Pharmacol, 46, 1577.
53. Shen S, Strobel HW. (1993) Role of lysine and arginine residues of cytochrome P450 in the interaction between cytochrome P4502B1 and NADPH-cytochrome P450 reductase. Arch Biochem Biophys, 304, 257.
54. Omata Y, Friedman FK. (1992) Cytochrome P450-benzphetamine interactions in the endoplasmic reticulum: studies using a monoclonal antibody to P450b. Biochemistry, 31, 8862.
55. Centeno F, Gutierrez-Merino C. (1992) Location of functional centers in the microsomal cytochrome P450 system. Biochemistry, 31, 8473.

56. Omata Y, Friedman FK. (1991) A fluorescence study of the interactions of benzo[a]pyrene, cytochrome P450c and NADPH-cytochrome P450 reductase. Biochem Pharmacol, 42, 97.
57. Mayer RT, Netter KJ, Heubel F, Hahnemann B, Buchheister A, Mayer GK, Burke MD. (1990) 7-Alkoxyquinolines: new fluorescent substrates for cytochrome P450 monooxygenases. Biochem Pharmacol, 40, 1645.
58. Kellis JT, Jr., Vickery LE. (1990) 6 alpha-fluorotestosterone: a nonaromatizable androgen inhibitor of aromatase cytochrome P450. Steroids, 55, 242.